STOCK TITAN
  1. Home
  2. News
  3. OPRX

OptimizeRx Corp - OPRX STOCK NEWS

Welcome to our dedicated news page for OptimizeRx (Ticker: OPRX), a resource for investors and traders seeking the latest updates and insights on OptimizeRx.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect OptimizeRx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of OptimizeRx's position in the market.

News
OptimizeRx Releases 2024 Environmental, Social, and Governance (ESG) Report
Rhea-AI Summary
OptimizeRx Corp. releases its 2024 Environmental, Social, and Governance (ESG) report, highlighting key achievements in governance, environmental efforts, employee support, and innovation. The report showcases the company's commitment to ESG best practices and transparency, including metrics across Governance, Planet, People, and Prosperity categories.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
none
-
News
OptimizeRx Reports Strong Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
OptimizeRx Corp. reported strong fourth-quarter and full-year 2023 financial results, with Q4 revenue reaching $28.4 million, a 44% increase year-over-year. The company acquired Medicx Health, significantly expanding its consumer footprint. DAAP deals increased to 24 in 2023 from six in 2022. Financial highlights include a 44% revenue increase in Q4, gross profit of $17.8 million, and a non-GAAP net income of $4.6 million for the quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.49%
Tags
earnings
-
News
OptimizeRx Named America’s Fastest-Growing Company for Fifth Year in a Row
Rhea-AI Summary
OptimizeRx Corp. secures a spot on the 2024 Financial Times’ Americas’ Fastest-Growing Companies list for the fifth consecutive year, ranking 253 with 36% revenue growth from 2019 to 2022. The market embraces OptimizeRx's Dynamic Audience Activation Platform (DAAP), an AI-powered solution connecting life sciences, healthcare professionals, and patients, enabling earlier treatment initiation and revenue growth potential.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
none
News
OptimizeRx Sets Fourth Quarter 2023 Conference Call for March 28, 2024 at 8:30 a.m. ET
Rhea-AI Summary
OptimizeRx Corp. (OPRX) will discuss preliminary, unaudited results for the fourth quarter in a conference call on March 28, 2024. The leading healthcare technology solutions provider aims to engage healthcare professionals and patients. Details for the call are provided, including toll-free and international numbers, conference ID, and webcast link.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.7%
Tags
earnings
-
News
OptimizeRx Provides an Update on the Timing of Earnings Call and Reaffirms Prior Revenue and Adjusted EBITDA Estimates for FY2023
Rhea-AI Summary
OptimizeRx Corp. reaffirms revenue and adjusted EBITDA estimates for FY2023, updates revenue guidance for 2024 due to accounting treatment change, and plans a conference call to discuss financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.12%
Tags
earnings
-
News
OptimizeRx Powers Walmart's ‘Specialty Pharmacies of the Community’ Outreach Effort
Rhea-AI Summary
OptimizeRx Corp. collaborates with Walmart to support Specialty Pharmacies of the Community (SPOCs) provider outreach initiative. The collaboration aims to help healthcare providers identify solutions for patients facing barriers to care, especially those with HIV and autoimmune conditions. OptimizeRx's Dynamic Audience Activation Platform (DAAP) will connect HCPs with Walmart's SPOCs network through targeted messaging, saving time and increasing awareness of available resources.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.07%
Tags
none
News
OptimizeRx to Participate in Upcoming Investor Conferences
Rhea-AI Summary
OptimizeRx Corp. (OPRX) announces participation in investor conferences to engage with investors. The Company will be present at Barclays 26th Annual Global Healthcare Conference and 36th Annual ROTH Conference for discussions and one-on-one meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.23%
Tags
conferences
-
News
OptimizeRx Announces Strategic Board Changes to Support Growth and Evolving Landscape
Rhea-AI Summary
OptimizeRx Corp. (Nasdaq: OPRX) announces changes to its Board of Directors, with Gus Halas retiring and Lynn O’Connor Vos assuming the role of Chairperson. The company aims to align with its growth plans, leveraging Vos's expertise in healthcare technology and life sciences to lead the next phase of growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
none
-
News
OptimizeRx Preannounces Select Expected 2023 Financials and Provides a Business Update
Rhea-AI Summary
OptimizeRx Corp. (OPRX) announced preliminary unaudited financials for 2023, with expected revenue exceeding the guidance range of $68-$70 million. The company closed the year with 24 deals, driving a sequential improvement in key performance indicators. Adjusted EBITDA for the fourth quarter is expected to reach a new high, primarily due to a higher margin solution mix. The integration of the Medicx Health acquisition is ahead of expectations, with most activities expected to be completed by the end of the first quarter of 2024. CEO Will Febbo expressed confidence in achieving 2024 revenue guidance of at least $110 million and at least 10% adjusted EBITDA margins.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.85%
Tags
none
News
OptimizeRx to Participate at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco
Rhea-AI Summary
OptimizeRx Corp. (OPRX) executives will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA from January 8-11, 2024. The presentation is scheduled for January 11, 2024, at 8:15 a.m. Pacific Time. Management will be available for institutional investor meetings on January 10th and 11th.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.98%
Tags
conferences
Stock OPRX logo
OptimizeRx Corp

Nasdaq:OPRX

OPRX Rankings

#3900 Ranked by Market Cap
#4677 Ranked by Stock Gains
N/A Ranked by Dividends

OPRX Stock Data

195.32M
15.06M
11.86%
72.33%
3.61%
Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
Professional, Scientific, and Technical Services
Link
United States
Rochester

About OPRX

optimizerx partners with pharmaceutical companies to offer electronic versions of their patient savings and support materials within the eprescribing workflow of leading electronic health record platforms. using the samplemd technology, providers can more efficiently distribute savings and support materials to their patients. the ecoupon technology, available in the eprescribing workflow of over 300,000+ providers, has expanded the distribution of savings and support materials to millions of patients throughout the us and aims to increase adherence rates and affordability of prescribed medications. about optimizerx corp. optimizerx corp. provides unique consumer and physician platforms to help patients better afford and comply with their medications, while offering pharmaceutical companies effective ways to expand awareness, affordability and adherence to their brands. for more information on samplemd, please call us at (877) 568-3840 or visit www.samplemd.com.